1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,282 | 0,340 | 12:11 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2026 | 126 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2026 for the GroupNet sales amounted to TSEK 2,147 (1,595)Result before tax amounted... ► Artikel lesen | |
| 10.03. | AcouSort AB: AcouSort receives prepayment of royalties | 273 | GlobeNewswire (Europe) | AcouSort AB today announced the signing of an amendment to its license and distribution agreement with the leading blood-gas analyzer company, Werfen. Under the amendment, Werfen will prepay minimum... ► Artikel lesen | |
| 25.02. | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2025 | 185 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.October - December 2025 for the GroupNet sales amounted to TSEK 2,459 (1,221)Result before tax... ► Artikel lesen | |
| 19.12.25 | AcouSort AB: AcouSort and MFX enter a collaboration to streamline future cell therapy manufacturing | 1.157 | GlobeNewswire (Europe) | AcouSort AB today announced it has entered a collaboration with MFX, a UK-based developer of next-generation scalable bioreactor platforms, to evaluate if AcouSort's technology can be paired with MFX's... ► Artikel lesen | |
| 15.12.25 | AcouSort AB: Stefan Blomsterberg elected new Chairman of the Board of AcouSort | 238 | GlobeNewswire (Europe) | AcouSort AB today announced that Stefan Blomsterberg has been appointed new Chairman of the Board, effective January 1, 2026.
Stefan Blomsterberg currently holds the position as CEO of CELLINK Bioprinting... ► Artikel lesen | |
| 26.11.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - September 2025 | 229 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
July - September 2025 for the GroupNet sales amounted to TSEK 1,248 (1,198)Result before tax... ► Artikel lesen | |
| 19.11.25 | AcouSort AB: AcouSort and Danish SeeQ Diagnostics sign technology evaluation agreement | 332 | GlobeNewswire (Europe) | AcouSort AB today announced it has signed a technology evaluation agreement with the Danish diagnostics company SeeQ Diagnostics concerning the evaluation of AcouSort's blood/plasma separation technology... ► Artikel lesen | |
| 22.09.25 | AcouSort AB: AcouSort receives new order boosting Central European collaboration | 233 | GlobeNewswire (Europe) | AcouSort AB today announced it has received a third order from a Central European company that develops diagnostic systems and medical devices. The company evaluates AcouSort's novel technology for... ► Artikel lesen | |
| ACOUSORT Aktie jetzt für 0€ handeln | |||||
| 27.08.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - June 2025 | 204 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
April - June 2025 for the GroupNet sales amounted to TSEK 1,551 (961)Result before tax amounted... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 55,44 | +2,29 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,356 | -0,88 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Second Quarter 2026 Financial Results on August 5 | ||
| SARTORIUS STEDIM BIOTECH | 163,40 | +0,49 % | AKTIEN IM FOKUS 2: Danaher enttäuscht Anleger - Auch Sartorius-Kurs leidet | (neu: Kurse mit Danaher im offiziellen Handel, Analystenstimmen) FRANKFURT/NEW YORK (dpa-AFX) - Der Quartalsbericht von Danaher hat im Diagnostikbereich am Dienstag international eine Welle der Enttäuschung... ► Artikel lesen | |
| BIOLIFE SOLUTIONS | 26,800 | +2,29 % | Repligen Corporation: Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media | Fast-tracks Repligen's leadership and customer solution offering in high-growth cell therapy market by adding BioLife's differentiated, high-margin recurring revenue business BioLife... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,485 | +0,06 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| CRESCENT BIOPHARMA | 14,100 | +3,68 % | Crescent Biopharma, Inc.: Crescent Biopharma Announces Grants of Inducement Awards | ||
| CG ONCOLOGY | 73,52 | 0,00 % | CG Oncology bladder cancer trial results published in Lancet | ||
| RELAY THERAPEUTICS | 18,640 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,630 | 0,00 % | Dyne Therapeutics Announces Pricing Of Upsized $375 Million Public Offering | ||
| KYMERA THERAPEUTICS | 110,05 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer | Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,720 | 0,00 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| VERA THERAPEUTICS | 35,180 | 0,00 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 52,74 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 60,12 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| ZENAS BIOPHARMA | 32,820 | 0,00 % | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen |
Das Unternehmen ACOUSORT AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,303 Euro und damit -4,42 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACOUSORT AB finden Sie auf Wallstreet Online.